Free Trial
NASDAQ:NRIX

Nurix Therapeutics Q3 2024 Earnings Report

Nurix Therapeutics logo
$9.57 -1.37 (-12.55%)
As of 09:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nurix Therapeutics EPS Results

Actual EPS
-$0.67
Consensus EPS
-$0.67
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Nurix Therapeutics Revenue Results

Actual Revenue
$12.59 million
Expected Revenue
$13.85 million
Beat/Miss
Missed by -$1.26 million
YoY Revenue Growth
N/A

Nurix Therapeutics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Friday, October 11, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Nurix Therapeutics' Q2 2025 earnings is scheduled for Thursday, July 10, 2025, with a conference call scheduled on Monday, July 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Nurix Therapeutics Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.
See More Nurix Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email.

About Nurix Therapeutics

Nurix Therapeutics (NASDAQ:NRIX), a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

View Nurix Therapeutics Profile

More Earnings Resources from MarketBeat